Welcome to our dedicated page for Humana SEC filings (Ticker: HUM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Humana Inc. (NYSE: HUM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K and quarterly reports on Form 10-Q as they are filed with the U.S. Securities and Exchange Commission. As a major participant in Medicare Advantage, Medicaid managed care and related health insurance lines, Humana uses these filings to report financial results, guidance, leadership changes and other material events.
Recent Form 8-K filings for Humana include Regulation FD disclosures reaffirming earnings guidance and providing reconciliations between GAAP earnings per common share and Adjusted earnings per common share (Adjusted EPS), which management uses to analyze core operating performance and inform planning and incentive compensation. Other 8-Ks describe results of operations for specific quarters, preliminary Medicare Advantage Star Ratings information, and leadership transitions in the insurance segment, such as the planned retirement of an Insurance Segment President and the appointment of new leaders for Medicare Advantage and the broader insurance business.
Filings also reflect Humana’s role as a health insurer and managed care organization. AM Best’s rating actions, while separate from SEC filings, complement the picture provided in regulatory reports by describing the financial strength and business profile of Humana’s health and dental insurance subsidiaries, collectively known as Humana Health Group, and by noting the contribution of the CenterWell segment as a non-insurance source of revenue and earnings.
On Stock Titan, investors and researchers can use AI-powered summaries to quickly interpret lengthy documents such as 10-K and 10-Q reports, focusing on topics that matter for a company like Humana: Medicare Advantage and Medicaid performance, Star Ratings dynamics, non-GAAP metrics like Adjusted EPS, capital structure, and risk disclosures. The filings page also surfaces insider and executive-related disclosures reported on Form 8-K, helping users track leadership changes and compensation-related arrangements referenced in those reports. Real-time updates from EDGAR combined with AI explanations make it easier to follow how Humana communicates its financial condition, strategic initiatives and regulatory developments over time.
Humana Inc. filed an update stating that senior management will meet with investors and analysts between September 1 and September 30, 2025, and intends to reaffirm its full-year 2025 guidance. The company continues to project approximately $13.77 in diluted earnings per common share (GAAP EPS) and approximately $17.00 in adjusted earnings per common share (Adjusted EPS) for the year ending December 31, 2025, consistent with guidance issued on July 30, 2025.
Humana explains that Adjusted EPS is a non-GAAP measure used alongside GAAP EPS to evaluate core operating performance and for planning and incentive compensation. For FY 2025, projected GAAP EPS of approximately $13.77 is adjusted by items such as $0.49 of amortization of identifiable intangibles, $3.01 of put/call valuation adjustments on certain minority interest investments, $0.44 related to value creation initiatives, $0.26 of impairment charges, and a cumulative net tax impact of $(0.97), resulting in projected Adjusted EPS of approximately $17.00. The company also notes it will not comment on 2026 Medicare Advantage Star Ratings until CMS releases final data in October.
Humana Inc. (HUM) Form 4 – insider equity change filed 08-05-2025. SVP & Chief Accounting Officer John-Paul W. Felter converted 211 restricted stock units under the 2019 Stock Incentive Plan on 08-01-2025 (Code M). Immediately upon vesting, 97 shares were sold (Code F) at $248.415 to cover tax obligations, a routine withholding transaction yielding no cash proceeds to the insider. Net of withholding, Felter’s direct common-stock holding rose by 114 shares to 1,881 shares. Derivative holdings fell to 115 RSUs after the conversion, and 1,203 additional RSUs remain reported in footnote (4). No open-market purchases or sales were disclosed. The activity represents scheduled vesting rather than discretionary trading, and the dollar value (<~$26k of tax-withheld shares) is immaterial relative to HUM’s market capitalization, suggesting limited signaling value for investors.
Humana Inc. (NYSE: HUM) filed its Q2-25 Form 10-Q. Premium and service revenues rose 10% YoY to $32.4 bn for the quarter and 9% YoY to $64.5 bn for the first half. Growth was driven by Medicare Advantage membership and higher services revenue.
Quarterly results weakened: operating income fell 4% to $1.1 bn, while net income dropped 20% to $545 m ($4.51 diluted EPS vs. $5.62). Benefit expense grew 10% and other expense jumped to $200 m, reflecting value-creation and impairment charges. The medical benefit ratio ticked up 90 bp to 89.8%.
Year-to-date performance stronger: YTD net income climbed 26% to $1.79 bn with diluted EPS of $14.81 (+26%), aided by lower benefit ratio (88.4%) and higher operating margins.
Balance sheet: cash & equivalents doubled to $4.0 bn; total assets $50.4 bn. Long-term debt rose to $12.6 bn after issuing $1.5 bn of new senior notes (5.55% 2035; 6.00% 2055) and retiring $600 m notes due 2025. A new $5 bn 5-year revolving credit facility replaced prior lines; no outstanding borrowings.
Capital return: $100 m share buybacks (0.4 m shares at $234 avg) and $0.885 quarterly dividend ($321 m YTD). Remaining authorization: $2.8 bn.
Key risks & items: Medicare Part D redesign effective 2025, ongoing cost-saving initiatives (additional charges expected), $32 m intangible impairment, and put/call obligations on WCAS clinic JV valued at $1.25 bn. Effective tax rate 24.6%. Shares outstanding 120.3 m.